Author Archives: Marisa Wexler MS

Europe Awaits Proposed New Framework for Sharing Health Data

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Bridge Joins With Cellion to Advance BBT-301 as IPF Ion Channel Therapy

Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…

AdAlta’s AD-214 Granted Patent Protection in China

The China National Intellectual Property Administration has granted AdAlta a patent covering AD-214, the biotech company’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The patent — number CN 107427574 B — entitled “CXCR4 binding molecules,” will expire in early January 2036. “China is now the second largest (and…

Ofev Negotiations Complete in Canada, Paving Way for Availability

Boehringer Ingelheim Canada has finished negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) — a partnership between the country’s provincial, territorial and federal governments — for Ofev (nintedanib), the company’s approved oral medication for progressive fibrosing interstitial lung diseases (PF-ILD). The pCPA conducts negotiations with drug manufacturers for treatments…